Skip to content

Further data on pegylated interferon in HCV/HIV coinfection

NRTI-sparing regimen achieves better viral suppression

Switch to atazanavir associated with cholesterol and triglyceride reductions

How much can we trust statistical models of the HIV epidemic?

Caribbean states announce first regional deal for cheaper ARVs

Scaling up MTCT programmes: learning from Zambia

Protease inhibitors may disappear within three years, predicts Robert Gallo

Superinfection despite strong immune response to existing virus

Impact of immigration and international travel on UK HIV and STI epidemics